Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares have declined amid heightened safety and regulatory concerns surrounding its lead gene therapy Elevidys, coupled with a wave of analyst downgrades and legal investigations. Below is a breakdown of recent developments that may influence the stock’s performance:

• TipRanks projects a potential 200% upside for SRPT if safety and regulatory hurdles for Elevidys are cleared.

• Unusually high options trading activity was reported, indicating speculative positioning or hedging ahead of catalysts.
• Cantor Fitzgerald assigned a Neutral rating on SRPT, reflecting a cautious stance.
• Morgan Stanley placed SRPT at Equal Weight, suggesting investors should wait for clearer data.

• Mizuho slashed its price target from $85.00 to $40.00 despite maintaining an "Outperform" rating, signaling diminished confidence in near-term upside.
• Stat News questioned the outlook for Sarepta’s gene therapy program, underscoring increasing regulatory scrutiny.
• Two patient fatalities in Elevidys trials led to a 42% stock drop, intensifying safety concerns among investors.
• Deutsche Bank issued a pessimistic forecast, cutting its outlook for SRPT shares.
• Goldman Sachs downgraded its rating to Hold, reflecting tempered expectations.
• Wells Fargo lowered its price target to $75.00 after reviewing trial setbacks.
• TD Cowen cut its rating to Hold with a $24.00 objective, highlighting risk/reward imbalance.
• BMO Capital Markets downgraded SRPT, citing broader sector headwinds.
• HC Wainwright moved to a Sell rating, flagging potential for further downside.
• Robert W. Baird reduced its expectations for Sarepta’s stock performance.
• Jefferies Financial Group lowered its price target to $54.00, adding to the bearish sentiment.
• Shares hit a new 12-month low following this cascade of analyst downgrades.
• Pomerantz LLP and Bleichmar Fonti & Auld LLP launched class-action investigations into whether Sarepta misled investors about Elevidys safety, creating legal overhang.